Amylyx Pharmaceuticals to Present at Needham Healthcare Conference

Got story updates? Submit your updates here. ›

Amylyx Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, announced that it will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The conference is a leading industry event that brings together healthcare companies, investors, and key opinion leaders to discuss the latest advancements in the field.

Why it matters

Amylyx's participation in the Needham conference is significant as it provides the company with an opportunity to showcase its pipeline and engage with the broader healthcare community. As a clinical-stage biotech firm, Amylyx's ability to attract investor interest and secure funding is crucial for the continued development of its therapies, which aim to address unmet needs in neurodegenerative diseases.

The details

During the conference, Amylyx's management team will deliver a corporate presentation and participate in one-on-one meetings with investors. The presentation will focus on the company's lead product candidate, AMX0035, a dual-mechanism therapy currently in late-stage clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.

• The 25th Annual Needham Virtual Healthcare Conference will take place on April 15, 2026.
• Amylyx Pharmaceuticals will present at the conference on that date.

What’s next

Following the conference, Amylyx will continue to provide updates on the progress of its clinical trials and regulatory submissions for AMX0035 as the company works towards potential approvals and commercialization of its lead therapy.